Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent:30-day stroke rate and complications

TY - JOUR

T1 - Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent:30-day stroke rate and complications

AU - von Schoenfeldt, Patrick

AU - Krützelmann, Anna

AU - Bußmeyer, Matthias

AU - Mpotsaris, Anastasios

AU - Rosenkranz, Michael

AU - Fiehler, Jens

AU - Weber, Werner

AU - Buhk, Jan-Hendrik

PY - 2014

Y1 - 2014

N2 - BACKGROUND AND PURPOSE: Analysis of procedural results and 30-day outcome after intracranial angioplasty and stenting (ICAS) with the balloon-expandable Pharos Vitesse stent system in carefully selected high-risk patients in two high-volume neurovascular centers.MATERIALS AND METHODS: 92 patients scheduled for elective ICAS using Pharos Vitesse between August, 2008 and August, 2011 were included. All patients showed high-grade intracranial stenosis and recurrent ischemic events despite best medical treatment at that time. The stroke rates and complications were divided into procedural and 30-day short-term events.RESULTS: Successful stent placement was achieved in all but one patient. Ischemic procedural complications occurred in three subjects. 30-Day complications and strokes were seen in four patients: two minor ischemic strokes, one fatal hemorrhage and one non-stroke-related death. Overall, strokes occurred in 6 out of 92 patients (6.5%, 95% CI 3.0% to 13.5%). The total stroke and death rate was 7.6% (95% CI 3.7% to 14.9%). No significant correlation with previously reported risk factors could be found, although a higher rate of ischemic strokes (four out of five) in the posterior circulation was recorded.CONCLUSIONS: In patients with intracranial stenosis who experience recurrent ischemic events despite best medical treatment, ICAS, using the balloon-expandable Pharos Vitesse stent, may still be considered as an individual treatment option in high-volume neurovascular centers.

AB - BACKGROUND AND PURPOSE: Analysis of procedural results and 30-day outcome after intracranial angioplasty and stenting (ICAS) with the balloon-expandable Pharos Vitesse stent system in carefully selected high-risk patients in two high-volume neurovascular centers.MATERIALS AND METHODS: 92 patients scheduled for elective ICAS using Pharos Vitesse between August, 2008 and August, 2011 were included. All patients showed high-grade intracranial stenosis and recurrent ischemic events despite best medical treatment at that time. The stroke rates and complications were divided into procedural and 30-day short-term events.RESULTS: Successful stent placement was achieved in all but one patient. Ischemic procedural complications occurred in three subjects. 30-Day complications and strokes were seen in four patients: two minor ischemic strokes, one fatal hemorrhage and one non-stroke-related death. Overall, strokes occurred in 6 out of 92 patients (6.5%, 95% CI 3.0% to 13.5%). The total stroke and death rate was 7.6% (95% CI 3.7% to 14.9%). No significant correlation with previously reported risk factors could be found, although a higher rate of ischemic strokes (four out of five) in the posterior circulation was recorded.CONCLUSIONS: In patients with intracranial stenosis who experience recurrent ischemic events despite best medical treatment, ICAS, using the balloon-expandable Pharos Vitesse stent, may still be considered as an individual treatment option in high-volume neurovascular centers.

U2 - 10.1136/neurintsurg-2013-011019

DO - 10.1136/neurintsurg-2013-011019

M3 - SCORING: Journal article

C2 - 24510379

VL - 7

SP - 188

EP - 193

JO - J NEUROINTERV SURG

JF - J NEUROINTERV SURG

SN - 1759-8478

IS - 3

ER -